We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Product
Advertisement

ANGPT2/TIE2: Attractive Targets for Improved Anti-angiogenic Cancer Therapy

ANGPT2/TIE2: Attractive Targets for Improved Anti-angiogenic Cancer Therapy


Angiopoietin-2 (ANGPT2) is a ligand of the receptor tyrosine kinase TIE2 (TEK). In conjunction with vascular endothelial growth factor (VEGF), ANGPT2-TIE2 signaling induces vascular sprouting. Inhibition of ANGPT2 shows promising results in preventing tumor angiogenesis, tumor growth, and metastasis in preclinical models, making it an attractive candidate to target in cancer.

ANGPT2 is highly upregulated at the early stages of tumor progression to drive neovessel formation. Conventional anti-VEGF therapies primarily target immature blood vessels in tumors. The combinational targeting of both ANGPT2 and VEGF pathways is now expected to improve clinical efficacy by expanding the target vessel population. Sino Biological has developed high-quality reagents to support the study of the ANGPT2/TIE2 signaling.

ANGPT2/TIE2 Pathway Proteins
ANGPT2/TIE2 Pathway Antibodies



About Sino Biological Inc
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates